Innate Pharma (IPHA) Short term Debt (2017 - 2025)

Innate Pharma has reported Short term Debt for 9 years, with the latest figure at $10.2 million in Q4 2025.

• For the quarter ending Q4 2025, Short term Debt rose 10.1% year-over-year to $10.2 million; the trailing twelve-month figure through Dec 2025 stood at $10.2 million (up 10.1% YoY), and the FY2025 full-year result was $10.2 million, up 10.1% from the prior year.
• Short term Debt for Q4 2025 stood at $10.2 million, up from $10.1 million in the prior quarter.
• The five-year high for Short term Debt was $35.2 million in Q4 2021, with the low at $2.1 million in Q4 2022.
• Historically, Short term Debt has averaged $12.7 million across 5 years, with a median of $9.6 million in 2023.
• The largest YoY upside for Short term Debt was 1277.31% in 2021 against a maximum downside of 99.88% in 2021.
• Innate Pharma's Short term Debt stood at $35.2 million in 2021, then tumbled by 93.9% to $2.1 million in 2022, then soared by 348.33% to $9.6 million in 2023, then slipped by 3.21% to $9.3 million in 2024, then rose by 10.1% to $10.2 million in 2025.
• The last three Short term Debt figures came in at $10.2 million (Q4 2025), $10.1 million (Q2 2025), and $9.3 million (Q4 2024), per Business Quant data.